ZA976538B - Method of preventing or treating pneumonia in immobilized patients with uridine triphosphate and related compounds - Google Patents

Method of preventing or treating pneumonia in immobilized patients with uridine triphosphate and related compounds

Info

Publication number: ZA976538B
Authority: ZA; South Africa
Prior art keywords: airways; secretions; patient; mucous; utp
Prior art date: 1996-07-23

Application number

ZA976538A

Other languages

English (en)

Inventor

Karla M Jacobus

H Jeff Leighton

Original Assignee

Inspire Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-23

Filing date

1997-07-23

Publication date

1998-07-09

1997-07-23 Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc

1998-07-09 Publication of ZA976538B publication Critical patent/ZA976538B/xx

Links

238000000034 method Methods 0.000 title abstract 5
PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 title abstract 4
PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 title abstract 4
206010035664 Pneumonia Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
229950010342 uridine triphosphate Drugs 0.000 title 1
230000028327 secretion Effects 0.000 abstract 4
230000035559 beat frequency Effects 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 2
230000001886 ciliary effect Effects 0.000 abstract 2
230000004936 stimulating effect Effects 0.000 abstract 2
DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 abstract 1
YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 abstract 1
239000000443 aerosol Substances 0.000 abstract 1
210000004081 cilia Anatomy 0.000 abstract 1
239000003889 eye drop Substances 0.000 abstract 1
229940012356 eye drops Drugs 0.000 abstract 1
239000012530 fluid Substances 0.000 abstract 1
230000000887 hydrating effect Effects 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
239000006194 liquid suspension Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000007923 nasal drop Substances 0.000 abstract 1
229940100662 nasal drops Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000006187 pill Substances 0.000 abstract 1
239000000843 powder Substances 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1
230000000717 retained effect Effects 0.000 abstract 1
239000007921 spray Substances 0.000 abstract 1
239000000829 suppository Substances 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1
230000000699 topical effect Effects 0.000 abstract 1
DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

ZA976538A 1996-07-23 1997-07-23 Method of preventing or treating pneumonia in immobilized patients with uridine triphosphate and related compounds ZA976538B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08685216 US5763447C1 (en)	1996-07-23	1996-07-23	Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds

Publications (1)

Publication Number	Publication Date
ZA976538B true ZA976538B (en)	1998-07-09

Family

ID=24751220

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA976538A ZA976538B (en)	1996-07-23	1997-07-23	Method of preventing or treating pneumonia in immobilized patients with uridine triphosphate and related compounds

Country Status (12)

Country	Link
US (2)	US5763447C1 (de)
EP (1)	EP0938322B1 (de)
JP (1)	JP2000516581A (de)
KR (1)	KR20000067983A (de)
CN (1)	CN1226169A (de)
AT (1)	ATE250420T1 (de)
AU (1)	AU727790B2 (de)
CA (1)	CA2261674A1 (de)
DE (1)	DE69725160T2 (de)
NZ (1)	NZ334204A (de)
WO (1)	WO1998003182A2 (de)
ZA (1)	ZA976538B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5900407A (en)	1997-02-06	1999-05-04	Inspire Pharmaceuticals, Inc.	Method of treating dry eye disease with uridine triphosphates and related compounds
US6319908B1 (en)	1996-07-03	2001-11-20	Inspire Pharmaceuticals, Inc.	Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5968913A (en) *	1996-07-03	1999-10-19	Inspire Pharmaceuticals, Inc.	Pharmaceutical compositions of uridine triphosphate
US5763447C1 (en) *	1996-07-23	2002-05-07	Inspire Pharmaceuticals	Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1998034942A2 (en)	1997-02-06	1998-08-13	Inspire Pharmaceuticals, Inc.	Dinucleotides and their use
US6696425B2 (en)	1997-02-06	2004-02-24	Inspire Pharmaceuticals, Inc.	Method of treating dry eye disease with purinergic receptor agonists
US6921755B2 (en)	1998-02-06	2005-07-26	Inspire Pharmaceuticals, Inc.	Method of treating dry eye disease with purinergic receptor agonists
US7223744B2 (en) *	1997-02-10	2007-05-29	Inspire Pharmaceuticals, Inc.	Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
TW593331B (en)	1997-07-25	2004-06-21	Inspire Pharmaceuticals Inc	Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6462028B2 (en)	1997-07-25	2002-10-08	Inspire Pharmaceuticals, Inc.	Method of promoting cervical and vaginal secretions
US6872710B2 (en) *	1997-07-25	2005-03-29	Inspire Pharmaceuticals, Inc.	Di(uridine 5′)-tetraphosphate and salts thereof
US6548658B2 (en) *	1997-07-25	2003-04-15	Inspire Pharmaceuticals, Inc.	Di-(uridine 5′)-tetraphosphate and salts thereof
CA2295515C (en) *	1997-07-25	2006-03-14	Inspire Pharmaceuticals, Inc.	Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
WO1999063927A1 (en) *	1998-06-08	1999-12-16	Michael Lansdale	System and method for acupressure therapy
CN100354296C (zh) *	1998-10-02	2007-12-12	雅玛山酱油株式会社	二尿苷四磷酸或其盐的晶体和其制备方法、以及制备该化合物的方法
ATE222920T1 (de) *	1998-10-02	2002-09-15	Yamasa Corp	Ein kristall von diuridine tetraphosphat oder ein solches salz und verfahren zu seiner herstellung, verfahren und herstellung der vorgenannten zusammensetzung
US6864243B1 (en)	2000-05-12	2005-03-08	Inspire Pharmaceuticals, Inc.	Method for treating retinal degeneration with purinergic receptor agonists
US7018985B1 (en)	2000-08-21	2006-03-28	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
US7452870B2 (en)	2000-08-21	2008-11-18	Inspire Pharmaceuticals, Inc.	Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en)	2000-08-21	2006-11-07	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
DE10108851A1 (de) *	2001-02-23	2002-09-12	Resprotect Gmbh	Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
AR034635A1 (es)	2001-06-25	2004-03-03	Inspire Pharmaceuticals Inc	Lubricacion de las articulaciones con agonistas del receptor purinergico p2y
KR20050043761A (ko) *	2001-11-06	2005-05-11	인스파이어 파마슈티컬스 인코퍼레이티드	염증성 질환의 치료 또는 예방 방법
US7334580B2 (en) *	2002-05-07	2008-02-26	Smaldone Gerald C	Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) *	2002-05-06	2009-10-27	The Research Foundation Of State University Of New York	Methods, devices and formulations for targeted endobronchial therapy
GB0417886D0 (en) *	2004-08-11	2004-09-15	Univ Cardiff	Method and means for enhanced pulmonary delivery
US7368439B2 (en) *	2005-06-15	2008-05-06	Bar - Ilan University	Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) *	2005-06-29	2010-12-14	Inspire Pharmaceuticals, Inc.	P2Y6 receptor agonists for treating lung diseases
WO2008024169A1 (en) *	2006-07-21	2008-02-28	Glsynthesis, Inc.	Reactive pyrophosphoric and bisphosphonic acid derivatives and methods of their use
JP2008199905A (ja) *	2007-02-16	2008-09-04	Snow Brand Milk Prod Co Ltd	乳酸菌生残性向上剤
US8618074B2 (en) *	2007-03-15	2013-12-31	Board Of Regents Of The University Of Texas System	GPCR enhanced neuroprotection to treat brain injury
EP2364086B1 (de)	2008-11-20	2016-09-14	Glsynthesis Inc.	Neue antithrombotische diadenosintetraphosphate und entsprechende analoga
US9119832B2 (en)	2014-02-05	2015-09-01	The Regents Of The University Of California	Methods of treating mild brain injury
KR20200079572A (ko) *	2015-06-05	2020-07-03	산텐 세이야꾸 가부시키가이샤	소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제
WO2017075535A1 (en)	2015-10-28	2017-05-04	Oxeia Biopharmaceuticals, Inc.	Methods of treating neurodegenerative conditions
CA3075962A1 (en) *	2017-09-17	2019-03-21	Glenn Fernandes	Lung cleansing apparatus and method

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9027968D0 (en) *	1990-12-22	1991-02-13	Fisons Plc	Method of treatment
EP0517573A1 (de) *	1991-06-05	1992-12-09	Synthelabo	Pharmazeutische Zusammensetzungen zur Behandlung von Atemwegserkrankungen
FR2677250B1 (fr) *	1991-06-05	1995-01-20	Synthelabo	Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
FR2684299B1 (fr) *	1991-12-02	1995-03-24	Synthelabo	Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique et de l'amiloride.
US5292498A (en) *	1991-06-19	1994-03-08	The University Of North Carolina At Chapel Hill	Method of treating lung disease with uridine triphosphates
AU7965694A (en)	1993-10-15	1995-05-04	Curators Of The University Of Missouri, The	Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5656256A (en)	1994-12-14	1997-08-12	The University Of North Carolina At Chapel Hill	Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5635160A (en) *	1995-06-07	1997-06-03	The University Of North Carolina At Chapel Hill	Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en)	1995-07-31	1997-05-13	University Of North Carolina At Chapel Hill	Method of detecting lung disease
JP3519199B2 (ja)	1996-02-06	2004-04-12	株式会社ソニー・コンピュータエンタテインメント	画像生成装置
US5900407A (en) *	1997-02-06	1999-05-04	Inspire Pharmaceuticals, Inc.	Method of treating dry eye disease with uridine triphosphates and related compounds
US6420347B1 (en) *	1997-03-27	2002-07-16	Inspire Pharmaceuticals, Inc.	Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US5837861A (en)	1997-02-10	1998-11-17	Inspire Pharmaceuticals, Inc.	Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
NZ332426A (en)	1996-03-27	2000-09-29	Univ North Carolina	Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds
US5789391A (en)	1996-07-03	1998-08-04	Inspire Pharmaceuticals, Inc.	Method of treating sinusitis with uridine triphosphates and related compounds
US6319908B1 (en) *	1996-07-03	2001-11-20	Inspire Pharmaceuticals, Inc.	Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5968913A (en)	1996-07-03	1999-10-19	Inspire Pharmaceuticals, Inc.	Pharmaceutical compositions of uridine triphosphate
US5962432A (en)	1996-07-03	1999-10-05	Inspire Pharmaceuticals, Inc.	Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate
US5763447C1 (en)	1996-07-23	2002-05-07	Inspire Pharmaceuticals	Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
AU4978897A (en)	1996-10-08	1998-05-05	Inspire Pharmaceuticals, Inc.	Method of early lung cancer detection via sputum induction and analysis of sputum to detect cancer associated substances
US6159952A (en)	1996-11-07	2000-12-12	Inspire Pharmaceuticals, Inc.	Method of treating bronchitis with uridine triphosphate and related compounds
WO1998034942A2 (en)	1997-02-06	1998-08-13	Inspire Pharmaceuticals, Inc.	Dinucleotides and their use
US6462028B2 (en)	1997-07-25	2002-10-08	Inspire Pharmaceuticals, Inc.	Method of promoting cervical and vaginal secretions
CA2295515C (en)	1997-07-25	2006-03-14	Inspire Pharmaceuticals, Inc.	Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
CA2300146A1 (en)	1997-08-29	1999-03-04	Richard C. Boucher, Jr.	Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
WO1999061012A2 (en)	1998-05-22	1999-12-02	Inspire Pharmaceuticals, Inc.	Therapeutic dinucleotide and derivatives
WO2000039145A1 (en)	1998-12-23	2000-07-06	The University Of North Carolina At Chapel Hill	Targeted gene transfer using g protein coupled receptors
MXPA01008547A (es)	1999-02-26	2003-06-06	Inspire Pharmaceuticals Inc	Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos.
US6555675B2 (en) *	2000-08-21	2003-04-29	Inspire Pharmaceuticals, Inc.	Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists

1996
- 1996-07-23 US US08685216 patent/US5763447C1/en not_active Expired - Lifetime
1997
- 1997-07-23 NZ NZ334204A patent/NZ334204A/en unknown
- 1997-07-23 CN CN97196639A patent/CN1226169A/zh active Pending
- 1997-07-23 DE DE69725160T patent/DE69725160T2/de not_active Expired - Fee Related
- 1997-07-23 ZA ZA976538A patent/ZA976538B/xx unknown
- 1997-07-23 KR KR1019997000504A patent/KR20000067983A/ko not_active Withdrawn
- 1997-07-23 WO PCT/US1997/012938 patent/WO1998003182A2/en not_active Ceased
- 1997-07-23 JP JP10507210A patent/JP2000516581A/ja active Pending
- 1997-07-23 US US09/202,825 patent/US6703376B2/en not_active Expired - Fee Related
- 1997-07-23 AT AT97934275T patent/ATE250420T1/de not_active IP Right Cessation
- 1997-07-23 EP EP97934275A patent/EP0938322B1/de not_active Expired - Lifetime
- 1997-07-23 CA CA002261674A patent/CA2261674A1/en not_active Abandoned
- 1997-07-23 AU AU37375/97A patent/AU727790B2/en not_active Ceased

Also Published As

Publication number	Publication date
DE69725160D1 (de)	2003-10-30
US5763447A (en)	1998-06-09
WO1998003182A3 (en)	1998-05-14
WO1998003182A2 (en)	1998-01-29
US5763447C1 (en)	2002-05-07
ATE250420T1 (de)	2003-10-15
EP0938322B1 (de)	2003-09-24
US20020155150A1 (en)	2002-10-24
KR20000067983A (ko)	2000-11-25
CA2261674A1 (en)	1998-01-29
JP2000516581A (ja)	2000-12-12
EP0938322A2 (de)	1999-09-01
US6703376B2 (en)	2004-03-09
NZ334204A (en)	2000-07-28
CN1226169A (zh)	1999-08-18
AU727790B2 (en)	2000-12-21
DE69725160T2 (de)	2004-08-12
AU3737597A (en)	1998-02-10

Publication	Publication Date	Title
US5763447C1 (en)	2002-05-07	Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
DE69716255D1 (de)	2002-11-14	Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
NO992197L (no)	1999-07-05	FremgangsmÕte for behandling av bronkitt med uridintrifosfater og relaterte forbindelser
WO1997035591A3 (en)	1998-01-22	Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
EP0841900A4 (de)	1998-06-10
MX9709637A (es)	1998-07-31	Dinucleotidos utiles para el tratamiento de enfermedades pulmonares.
CA2240717A1 (en)	1997-06-26	Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
EE04330B1 (et)	2004-08-16	Levosimendani transmukoossed koostised ja nende kasutamine ravimi valmistamiseks
EG17992A (en)	1991-08-30	Preparation of a medicament for arthritis and theumatism
JPH10130148A (ja)	1998-05-19	ネブライザー用組成物
JPH10203988A (ja)	1998-08-04	鼻茸および鼻粘膜の浮腫性病変の治療剤
UA36166A (uk)	2001-04-16	Спосіб лікування запальних захворювань підшлункової залози
KR890003399A (ko)	1989-04-14	약리적 활성 화합물 및 용도